SNIBE(SZ:300832)2022-04-21 16:00Financial Performance - The company's revenue for Q1 2022 reached ¥742,834,914, representing a 39.53% increase compared to ¥532,371,365 in the same period last year[4]. - Net profit attributable to shareholders was ¥308,478,491, an increase of 83.46% from ¥168,144,761 in the previous year[4]. - The total profit for the same period was 358.14 million RMB, an increase of 76.23% compared to the previous year[15]. - The company achieved a revenue of 742.83 million RMB in Q1 2022, representing a year-on-year growth of 39.53%[40]. - Net profit for Q1 2022 was CNY 308,478,491.40, compared to CNY 168,144,761.01 in Q1 2021, indicating a year-over-year increase of about 83.5%[46]. Cash Flow - The net cash flow from operating activities was ¥180,613,025, up 52.03% from ¥118,803,772 in the same period last year[10]. - The net cash flow from operating activities was ¥180,613,025.70, which is an increase of approximately 52.1% from ¥118,803,772.88[48]. - The net cash flow from investing activities improved by 36.93%, with a net outflow of ¥198,467,897.58 compared to ¥314,681,230.06 in the previous year[10]. - The net cash flow from investment activities was -¥198,467,897.58, an improvement from -¥314,681,230.06 in the previous period[49]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,394,592,241.84, a 4.22% increase from ¥6,135,507,556.27 at the end of the previous year[4]. - Total liabilities decreased to ¥460,929,290.47 from ¥523,508,864.94, a reduction of approximately 11.9%[19]. - The company's equity attributable to shareholders increased to ¥5,933,662,951.37 from ¥5,611,998,691.33, representing a growth of about 5.7%[19]. - The company's total current assets amounted to CNY 4.70 billion at the end of Q1 2022, up from CNY 4.50 billion at the beginning of the year[42]. Research and Development - Research and development expenses increased by 45.33% to ¥58,500,711 from ¥40,254,361 in the same period last year, reflecting the company's commitment to innovation[9]. - R&D expenses increased to ¥58,500,711.08 from ¥40,254,361.51, representing a growth of 45.2% year-over-year[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,925[11]. - The largest shareholder, Tibet New Industry Investment Management Co., Ltd., held 26.84% of the shares, amounting to 211,177,400 shares[11]. - The company plans to lift restrictions on shares held by major shareholders on May 12, 2023, affecting a total of 518,814,829 shares[14]. Operational Metrics - The company sold and installed 1,648 automated chemiluminescence analyzers in Q1 2022, including 148 units of the MAGLUMI X8 model[15]. - The number of terminal customers served by the company's products exceeded 7,900, with 855 being top-tier hospitals, resulting in a coverage rate of 54.11%[15]. - The gross margin for the main business improved by 1.02% due to adjustments in instrument sales policies[15]. - The net profit margin improved by 9.94% year-on-year as the impact of the 2020 restricted stock incentive plan gradually diminished[40].